Thank Hello, conference Financial Paul. Kellen, morning everyone, you, our and Chief second call. by welcome quarter Officer. our this to I'm joined Scott
Before we a at the Medtronic, Executive was and he the to to Kuntz our of a begin Board Chief that, served a as Chief of member President Medical Medtronic. President, where moment he Officer, Vice Kuntz want Scientific from take to Directors. Officer Committee. welcome retired Richard Neuromodulation morning, this to and Dr. Dr. Senior Prior I recently
Dr. in diseases Academy publications. National of an Hospital the has national at XXX has he an Before of original Biometrics Brigham served numerous as committees and Institutes the authored directed in trials served also was Officer Division Medicine Chief in the an Harvard Clinical as and Boston. in Medicine Health. Boston. as Cardiologist the of Interventional division cardiovascular He Medical Research and of of of Chief also Harvard He Kuntz Women's multi-center at School, Clinical adviser Scientific over Professor National and Institute Medtronic, the of regional Associate Founder to clinical multiple and and the
Board. and and of experience our skill Board. grateful are Rick our to the knowledge We complements broadens set His have join
Turning back to update. our
an two the hold of The important The and financing, lifting of $XX.X and our FDA's for raising of shareholders: million. the proceeds on ReMEDyX clinical completion trial at-the-market gross milestones second DiaMedica stroke our saw quarter
FDA for contract a the this immediately clinical vendors the new current hold announced selected or FDA. as XX, With stroke clinical reengaged Phase the ischemic space. June On had Starting organization on our treatment experience fully our acute we have a in with we that and with DMXXX strong research study support with X/X the studying decision, stroke AIS. ReMEDyX lifted trial,
many working we I preparing great As our can Recall there's leg a for key of of know, the a excited vendors CRO, of our from deal is a a dozen last with involved of sites under you already resumption that entire everyone clinical bit registrational focused work up advisors have team the on as trial. assure and and supporting with pivotal we approximately have trial. that year. contract for
evaluating addition viewed rate our we more being to of countries Additionally, enroll to are able the also in outside clinical US US enrollment increase the than quickly their of now sites as counterparts.
our Our enabling with deliver goal clinical and been conclusion past team in It data year. that mind package of FDA a ReMEDyX the DMXXX. expanded and improve over the complete has objective to clinical accept FDA the trial, this the is we at clean to to the
timing vendors upon timeline estimated But have are the to has the finalized. for today, not patient been been of key and the multiple the that enrollment. final with resumption be As pursuing all based interim will others, down of come The actual analysis actively for our yet enrollment before preparations engaged discussions are The end of optimistic of enrollment. pace XXXX. and CRO can we completed
more order the enrollment reach our with are and study raise, final the that stress increase both ultimately which more significantly brought to quickly. globally the intent with analysis interim pursue recent to want capital to in the to able capital we than rate in expanding I anticipated,
on the conducting clarity single-ascending We call. the provide expect Phase previously dose a to we a bags at IV we've note, XC overall to our PVC same IV using of trial. as discussed, in QX ReMEDyX On as study are and earnings timeline in volunteers more healthy the open-label, related be able DMXXX
X.X demonstrated we drug our level similar targeted stroke prior The level, to study under desired forward first dose that concentration is China range, the reported the to trial urine-derived used going part and safety in in ReMEDyX the KLKX human dose the of Phase of name kallikrein. protein levels kg our the blood this a level X therapeutic per microgram of demonstrated believe widely the also It the achieved trial. planned used be IV level our that KLKX product
We were able of methods Phase a to ACE the XC received dose three hypertensive the planned using per patients updated in These on ReMEDyX cohort fourth report patients microgram consisting completed today that the inhibitors. we the X.X kg trial. also for study,
patients, clinical in additional participants blood that the combined We IV further physician believe or current been the pressure. these the patients assurance We level ReMEDyX investigators instances all correct there results from trial. are identified provide will ACE has pleased may that including the and dose no received safely full be that to and hypotension IV of see to data potential dose were enrolled drops large and in
to Turning milestone. second our
completed potential proceeds at during and market. who a financing million investors straight $XX was remain the sheet about coverage were by patients. for priced $XX.X portion of quarter. Gross offering treatment to We million the capital compelling led end option bringing stroke over of $XX.X quarter. net existing the of offer past and a shares, The from strengthened significant this the raise In warrant new contributed DMXXX to its balance cash enthusiastic offering common we our and proceeds million, also an significantly our no were the at balance June,
$XXX,XXX. had We who from Board also and team excellent our participation management collectively invested
the us our interim have the We analysis we believe drive therapeutic development that the We enabling a in our has impact of It in on are not a DMXXX now signal remaining years capital who beneficial significant us year. cash to a patient the complete has put a interim of potential the believe where approval stroke grateful we that analysis. over We with to XX tPA. position have set to seen of can since the investors destiny. we to now patients, approximately sufficient one runway focus
updated patients, want which action key the in in turn to I your new deck I DMXXX's Scott, over increasing applies in by the the on that slide ischemic illustrates locally to attention as corporate the collateral call receptors based to Before and by created, much expressed as circulation. the bradykinin our are mechanism in stroke, X caused call highly of may upregulated as also the to conditions mechanism This ischemic models. role increase to brain message DMXXX upon cells we a a had video in animal penumbra. it The in is stroke that specifically, of higher further testing arteries response be XX-fold endothelial
of titled Care to collateral can Treatments. Patient outcomes. website to the www.diamedica.com and in brain, we scrolling significantly greater number the receptors blood We our section upregulated the of be lead to basal affected circulation this believe down page front DMXXX, found area video the believe with be X with augmenting the oxygen. the flow a ischemic may penumbra, the penumbra By brain causing increase the activated, will improved Innovative Advancing at to tissue focal on This improved bradykinin dilation and beneficial and patient in salvage
I Scott to highlights. the would to call like Kellen to the review turn financial now
